Edwards Lifesciences: Transcatheter Plan Remains On Track
This article was originally published in The Gray Sheet
Executive Summary
Edwards Lifesciences' European sales of its next-generation Sapien XT transcatheter aortic heart valve are now the firm's biggest growth engine, but most eyes are fixed on progress toward introducing a first-generation device on the U.S. market next year.